An open-label Phase 1 trial by Prasanna et al. in 2022 has found that coupling phenelzine (an LSD-1 inhibitor) with Nab-Paclitaxel (a chemotherapy agent) for metastatic breast cancers has the potential to eliminate circulating tumour cells with aggressive mesenchymal phenotype [122]. Here, KDM1A is linked to breast carcinoma.